European Journal of Immunology

Author Guidelines

These author guidelines can also be downloaded as a PDF version here.

Sections

1. Submission and Peer Review Process
2. Article Types
3. After Acceptance

1. Submission and Peer Review Process

Once you have checked the Aims and Scope of the European Journal of Immunology and the submission materials have been prepared in accordance with these Author Guidelines (please note that this journal offers simple first (free format) submission, manuscripts should be submitted online at

For help with submissions, please click on “Help” in the top right hand of ScholarOne™ Manuscripts. You can also contact the editorial office: [email protected]

This journal does not charge submission fees but there are publication fees.

Article Preparation Support

Wiley Editing Services offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence.

Also, check out our resources for Preparing Your Article for general guidance about writing and preparing your manuscript.

Simple first (Free Format) submission

Since November 2016, the European Journal of Immunology has been offering simple first (Free Format) submission for an easier, streamlined submission process.

Before you submit, you will need:

• Your manuscript: this should either be a single file including text, figures, and tables, or separate files—whichever you prefer. All required sections should be contained in your manuscript but do not need to be in European Journal of Immunology order or format. Figures and tables should have legends and the data should be reproducible. References may be submitted in any style or format, as long as it is consistent throughout the manuscript. Supporting information should be submitted in separate files. If the manuscript, figures or tables are difficult for you to read, they will also be difficult for the editors and reviewers, and the editorial office will send it back to you for revision. Your manuscript may also be sent back to you for revision if the quality of English language is poor.
• An ORCID ID, freely available at https://orcid.org. (Why is this important? Your article, if accepted and published, will be attached to your ORCID profile. Institutions and funders are increasingly requiring authors to have ORCID IDs.)
• The title page of the manuscript including your co-author details, affiliations and email addresses (Why is this important? We need to keep all co-authors informed of the outcome of the peer review process.)
• Statements relating to our ethics and integrity policies should be included before the References. These may include any of the following (Why are these policies important? We need to uphold rigorous ethical standards for the research we consider for publication):
• data availability statement
• funding statement: all funding sources for the study should be included in the Acknowledgements
• conflict of interest disclosure
• ethics approval statement: human and animal studies
• patient consent statement
• permission to reproduce material from other sources
• clinical trial registration
• Author contributions: each author’s contribution to the article should be detailed
• Acknowledgements

If you are submitting your manuscript as a single file, please select “Submission file” as the file designation.

To submit, login here and create a new submission. Follow the submission steps as required and submit the manuscript.

Open Access

This journal is a: subscription journal that offers an open access option. You’ll have the option to choose to make your article open access after acceptance, which will be subject to an article publication charge (APC). You can read more about APCs and whether you may be eligible for a discount or full payment through your institution.

Preprint policy:

Please find the Wiley preprint policy here.

This journal accepts articles previously published on preprint servers. You may also post the submitted version of a manuscript to a preprint server at any time. You are requested to update any pre-publication versions with a link to the final published article.

Refer and Transfer Program

This journal participates in Wiley’s Refer & Transfer program.

If your manuscript is not accepted at your first-choice journal, you may receive a recommendation to transfer the manuscript to another suitable Wiley journal, either through a referral from the journal’s editor or through our Transfer Desk Assistant.

Data Sharing and Data Availability

This journal expects data sharing. Review Wiley’s Data Sharing policy where you will be able to see and select the data availability statement that is right for your submission.

Data Citation

Please review Wiley’s Data Citation policy.

Data Protection

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication. Please review Wiley’s Data Protection Policy to learn more.

Funding

You should list all funding sources in the Acknowledgements section. You are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature.

Authorship

All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version. Review editorial standards and learn about authorship criteria. Mini-reviews and reviews should have a maximum of three authors unless agreed with the editorial office in advance.

ORCID

This journal requires ORCID. Please refer to Wiley’s resources on ORCID.

Reproduction of Copyright Material

If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is your responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley’s Copyright Terms & Conditions FAQ.

The corresponding author is responsible for obtaining written permission to reproduce the material "in print and other media" from the publisher of the original source, and for supplying Wiley with that permission upon submission.

Title Page

The title (first) page of the main text file should only contain: 

1. A brief informative title containing the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips) and should be no more than 150 characters including spaces;
2. The full names (including forenames) of the authors — middle names should be indicated by initials only and surnames should be indicated by underlining;
3. The author's institutional affiliations where the work was conducted, with a footnote for the author’s present address if different from where the work was conducted;
4. Name, postal address and e-mail of the corresponding author
5. Keywords (maximum of 5)
6. A list of abbreviations used. If an abbreviation is used three or more times in the text it should be included in the abbreviations list and defined the first time it is used in the abstract and in the main text. If it is used less than this, it should be defined in full each time it is used.

Main Text File

The main text file should be in Word or PDF format and include:

• A title page
• Abstract (maximum 200 words) if applicable (see article types)
• Main body: formatted according to article type
• References
• Tables (each table complete with title and footnotes)
• Figures: Figure legends must be added as a complete list in the text. The data should be reproducible, i.e. contain an appropriate number of samples, replicates, animals, patients and independent experiments (the total number of experiments performed and the number of samples, replicates, animals or donors per experiment should be clearly stated). Full statistical analysis should be provided, including the name of each statistical test used, a description of the comparisons made to obtain the p values (if not clearly indicated in the Figures), and a description of how the data are presented data e.g. SD, SEM etc. The legends should provide all this information, as well as explaining all symbols, values etc. used if a key is not provided in the Figures. Authors are encouraged to analyze data across multiple experiments and should note that analyzing replicates within a single experiment does not provide information regarding experimental reproducibility. Please also see the best practice regarding Figures and legends.

For animal studies, the legend or Materials and Methods should state the age, gender, genotype and housing arrangements of the animals, detailing any co-housing of animals of different experimental groups, particularly genetically different animals, and the length of time of such co-housing. Authors are also recommended to upload a health report of their animal facilities as Supporting Information. It should be remembered that it is not scientifically valid to compare KO mice bred amongst each other with WT mice purchased from a vendor or to breed transgenic mice without genotyping. Littermate controls will be requested as appropriate. For further information, please see this Commentary.

Please note that submitted manuscripts that do not contain complete information about the number of experiments performed, as well as the number of samples (biological or technical replicates) per experiment, will be unsubmitted, and manuscripts returned to authors for clarification.

Reference Style

This journal uses Vancouver reference style; as the journal offers simple first (free format) submission, however, this is for information only and you do not need to format the references in your article. This will instead be taken care of by the typesetter. Regardless of reference style used, please list all authors in the reference list. 

Figures and Supporting Information

Figures, supporting information, and appendices should be supplied as separate files. You should review the basic figure requirements for manuscripts for peer review, as well as the more detailed post-acceptance figure requirements. Please note the ethical considerations detailed on the last page of the figure requirements; authors must be able to produce all data in their raw format upon editorial request.

All figures of your manuscript will undergo an integrity check. In case of any doubt, raw data will be requested. Publication will proceed on the condition that all final files comply with the journal integrity checks. In the event that any file does not comply with our integrity checks, the journal reserves the right to rescind this decision, or, alternatively, you may be contacted to resolve any concerns raised by these checks

View  Wiley´s FAQs on supporting information. Of note, Supporting Information is not edited but is posted online as received. Please also note that Materials and methods are not allowed in the Supporting Information except for Notes and Insights (mandatory), Technical Reports (optional) or unless the Materials and Methods pertain ONLY to data in the Supporting Information.

Best practice examples: Figures and legends

Reproducibility

To report on reproducibility: please detail all key experimental information, including the number of samples, replicates, animals/donors per experiment, the total number of experiments performed, as well as the statistical analysis and the description of how the data are presented data e.g. SD, SEM. Please see Fig. 1 for an example.

Flow cytometry analysis

Please show the full gating strategy used. This should include the position of positive and negative controls and essential information, such as the percentage of cells in the region or gate or event count, and statistics as appropriate. Axis legends should include the marker (e.g. antigen) and the fluorochrome/dye used, and show a numbered scaling (log/lin). For more information how to prepare flow cytometry data analysis for publication see the EJI flow cytometry resource: Guidelines for the use of flow cytometry and cell sorting in immunological studies. Adherence to the Guidelines should be noted in the Materials and Methods. Please also see Fig. 3 for an example in an article.

If multiple experiments use the same gating, please show this only once. If space is limited, you may wish to include this information as Supporting Information. Please see this example of Supporting Information detailing the gating.

Microscopy

Please show scale bars and describe the length of the scale bar either in the text or in the image. Please see Fig. 3 for an example.

Western blots

Please show loading controls, MW markers and clearly indicate if lanes were cropped or spliced for presentation purposes. If blots have been cropped or spliced, please provide the raw data as Supporting Information. Please see Fig. 6 for an example.

Please also refer to the Appendix for detailed explanation of data sharing and assays.

Cell line research

For papers containing cell lines the following information should be provided in the methods section.

• The species, sex, tissue of origin, official cell line name and Research Resource Identifier (RRID).
  • Dates and timeline of described experiments, including passage number information (especially important for finite cell lines), may be requested.
  • Avoid misspelled identifiers (e.g. the incorrect use of NKM45, in the place of MKN45).
  • Official name and RRID are not applicable to primary cells.
• The source/supplier of the cell line and when it was obtained.
  • Documentation of the origin may be requested, which should include details on the creation of in-house cell lines and where externally sourced cell lines were first established.
• Confirmation that the cell line was authenticated for the described experiments (including the % match result and method used) and has not been previously reported as misidentified or contaminated (see databases below).
  • The expectation is that experiments were performed with verified cells (following STR profiling performed at the beginning and end of the described study), which are not listed within the databases below.
  • Documentation for the % match result and dates of testing may be requested.
  • Additional information on in-house or external testing may be requested.
  • If the cell line is listed within the databases below, the rationale for its use must be provided. The use of cross-contaminated cell lines is not expected to be justifiable.
  • Established cell lines without reference profiles require authentication to demonstrate no matches to other cell lines or evidence of being problematic.
• Confirmation that the cell line was free of mycoplasma contamination for the described experiments.
  • The expectation is that experiments were performed with confirmed mycoplasma free cells (this includes cell lines used for virus production etc). At least the latest passage of the cell line (when the cells were used) must have been tested using cell pellets or cell samples (not supernatant) and confirmed negative.
  • Documentation for mycoplasma result and dates of testing may be requested.
  • Additional information on in-house or external testing may be requested.

If one or more of the above are unknown, this must be stated and the rationale for the use of the cell line provided. Further guidance on misidentification and contamination is available from the International Cell Line Authentication Committee (ICLAC) register, the NCBI misidentified cell line database and Cellosaurus problematic cell line database.

Cover letter, ethics and permissions

Please refer to the section Guidelines on Publishing and Research Ethics in Journal Articles and that detailing required manuscript statements, as well as the information detailed here.

Manuscripts must be accompanied by a cover letter from the corresponding author. By submitting this letter, the corresponding author accepts responsibility for all statements contained within it.

The letter must detail in no more than 250 words the aim of the study, the novel results obtained and how the study advances our knowledge. The cover letter should not merely repeat the Abstract of the manuscript but should clearly and accurately describe the significance of the study for those working within/outside the field. Bullet points are a recommended way of communicating this information.

Please note that EJI’s policies help you avoid being scooped and authors requesting fast track processing, i.e. submitting either a ‘Rapid Research Article’ or a ‘Rapid Short Communication’, must also detail why the study warrants rapid review and publication, explaining the study’s superior significance for the immunological community and potentially competitive situation. Cover letters not including this information for ‘‘Rapid’’ papers will result in the manuscript being treated as a regular submission and the manuscript will not be fast-tracked.

Cover letter statements 

Every cover letter must also contain clear statements covering all the following points, indicating which option applies (if more than one), detailing those that are not applicable and providing any additional information as necessary:

1)         All authors concur with the submission.

2)         All funding for the studies in the manuscript, together with the names of the principal funding recipients, are listed in the Acknowledgements.

3)         All persons cited in the manuscript by way of the Acknowledgements, personal communications, unpublished observations/data concur with the citation. Any data cited in the manuscript that has been generated by persons not listed as authors, i.e. personal communications, must be accompanied by a written permission letter from the person cited. Permission letters e-mailed to [email protected] are acceptable.

4)         The work has not been published elsewhere, either completely, in part, or in another form.

5)         The manuscript has not been submitted to another journal and will not be published elsewhere within one year after its publication in this journal.

6)         The manuscript does/does not contain experiments using animals. The permission of the national or local (institutional review board (IRB)) authorities (giving the permission or the accreditation number of the laboratory and of the investigator) should be stated if animal experiments are included. If no such rules or permissions have been implicated in the particular country, this must be stated.

7)         The manuscript does/does not contain human studies. If such studies are included, it should be stated that local Ethical Committee (institutional review board (IRB)) approval was received for the studies and that the informed consent of all participating subjects was obtained.

Permission statements relating to animal and human studies (points 6 and 7) must also be included in the text of the manuscript.

8)         Any financial/commercial conflicts of interests have been disclosed. Such conflicts should be detailed in the covering letter

Financial/commercial conflicts of interests must also be stated in the manuscript after the Acknowledgements.

9)         Any papers by the authors that are under consideration or in press with other journals and not yet available online and are related to the manuscript submitted to the European Journal of Immunology have been submitted as supporting information.

Peer Review

This journal operates under a single-blind, transparent peer review model. Papers will only be sent to review if the Executive Committee determines that the paper meets the appropriate quality and relevance requirements.

In-house submissions, i.e. papers authored by Executive Committee or Editorial Board members of the title, will be sent to Executive Committee members unaffiliated with the author or institution and monitored carefully to ensure there is no peer review bias.

Wiley's policy on the confidentiality of the review process is available here.

This journal is participating in a pilot on Peer Review Transparency and you have the choice to opt-out during the submission process. By submitting to this journal, you agree that the reviewer reports, their responses, and the editor’s decision letter will be linked from the published article to where they appear on Publons in the case that the article is accepted. Reviewers can choose to remain anonymous unless they would like to sign their report.

This journal participates in Wiley’s Transfer Desk Assistant program.

Guidelines on Publishing and Research Ethics in Journal Articles

The journal requires that you include in the manuscript details IRB approvals, ethical treatment of human and animal research participants, and gathering of informed consent, as appropriate. You will be expected to declare all conflicts of interest, or none, on submission. Please review Wiley’s policies surrounding human studies, animal studies, clinical trial registration, biosecurity, and research reporting guidelines.

This journal follows the core practices of the Committee on Publication Ethics (COPE) and handles cases of research and publication misconduct accordingly.

This journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley’s Top 10 Publishing Ethics Tips for Authors and Wiley’s Publication Ethics Guidelines.

2. Article Types

Please note that:

• The maximum length of the title of an article is 150 characters including spaces. See also Wiley's best practice SEO tips.
• Subheadings within a Section (e.g. within Results) should be no more than 100 characters long including spaces.

*Word limits include the full text of the manuscript (Title page, Abstract, Section headings, subheadings, statements relating to ethics and integrity policies, Figure legends and Tables) but exclude references and exclude, if present, Supporting information.

** ‘’Data Limitations and Perspectives’’ aims to highlight key considerations regarding data limitations and future challenges mentioned in the Discussion section. It is a section dedicated to discussing study limitations, acknowledging referees' critiques that were not fully addressed experimentally (when applicable), and exploring new challenges and directions in the field in a concise and transparent manner. For further information, refer to the editorial ''Communication and transparency at EJI: Supporting authors through their publishing experience''. 

Please note that there is a publication fee, which is linked to the length of a typeset article;  Correspondence and commissioned articles are exempt from the fee. The recommended limits typically correspond to a 7-page research article and a 5-page short communication but this cannot be guaranteed as Figure/Table size greatly influences the final number of typeset pages.

3. After Acceptance

First Look

After your paper is accepted, your files will be assessed by the editorial office to ensure they are ready for production. You may be contacted if any updates or final files are required. Otherwise, your paper will be sent to the production team.

Wiley Author Services

When an accepted article is received by Wiley’s production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. You will be asked to sign a publication license at this point as well as arrange payment of the open access fee if applicable.

Copyright & Licensing

You may choose to publish under the terms of the journal’s standard copyright agreement, or Open Acess under the terms of a Creative Commons License.

Standard re-use and licensing rights vary by journal. Note that certain funders mandate a particular type of CC license be used. This journal uses the CC-BY/CC-BY-NC/CC-BY-NC-ND Creative Commons License.

Self-Archiving Definitions and Policies: Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions.

Proofs

Authors will receive an e-mail notification with their proofs included as a pdf. Authors should also make sure that any renumbered tables, figures, or references match text citations and that figure legends correspond with text citations and actual figures. Proofs must be returned within 48 hours of receipt of the email.

Article Promotion Support

Wiley Editing Services offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves.

Author Name Change Policy

In cases where authors wish to change their name following publication, Wiley will update and republish the paper and redeliver the updated metadata to indexing services. Our editorial and production teams will use discretion in recognizing that name changes may be of a sensitive and private nature for various reasons including (but not limited to) alignment with gender identity, or as a result of marriage, divorce, or religious conversion. Accordingly, to protect the author’s privacy, we will not publish a correction notice to the paper, and we will not notify co-authors of the change. Authors should contact the journal’s Editorial Office with their name change request.

Correction to authorship

In accordance with Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics and the Committee on Publication Ethics’ guidance, the European Journal of Immunology will allow authors to correct authorship on a submitted, accepted, or published article if a valid reason exists to do so. All authors – including those to be added or removed – must agree to any proposed change. To request a change to the author list, please complete the Request for Changes to a Journal Article Author List Form and contact either the journal’s editorial or production office, depending on the status of the article. Authorship changes will not be considered without a fully completed Author Change form. [Correcting the authorship is different from changing an author’s name; the relevant policy for that can be found in Wiley’s Best Practice Guidelines under “Author name changes after publication.”]

Appendix

Graphical TOC

The journal’s table of contents will be presented in graphical form with a brief abstract.

The table of contents entry consists of 2-3 sentences of text (no more than 80 words) summarizing the key findings presented in the paper and a figure that conveys the main message of your article in a simple and colourful manner.

The image supplied should fit within the dimensions of 50mm x 60mm and be fully legible at this size.

Publication Fees

There are no charges for color figures.

For authors who wish to choose the open access option, the article publication charge is Euro 3550/USD 4120/GBP 2940 (plus tax where applicable).

For authors who do not choose open access option, the article publication charges (plus tax where applicable) are as follows:

• Euro 500 for Technical Reports/Notes and Insights
• Euro 1000 for Short Communications longer than 5 typeset pages
• Euro 1600 for Research Articles longer than 7 typeset pages

To calculate the approximate number of pages your typeset article will have, count the number of text pages, tables and figures and divide the total by three. If your article is shorter than the indicated number of pages for Short Communications/Research Articles and is not open access, there is no fee.  An invoice will be sent approx. three weeks after publication of the issue.

If you have any further inquiries, please contact our Production Department at: [email protected].

Species Names

Upon its first use in the title, abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used.

Genetic Nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see varnomen.hgvs.org, where examples of acceptable nomenclature are provided.

T-cell assays (MIATA)

Authors are encouraged to provide information on T-cell assays according to MIATA (Minimal Information About T-cell Assays) guidelines. MIATA is a reporting framework intended to provide transparency of experimental conditions and to facilitate data reproducibility by independent research groups. Authors who have documented their T-cell assays according to MIATA guidelines are requested to include this information in the Materials and methods section (e.g. The T-cell assays were carried out as follows: (description according to MIATA guidelines); the authors declare that the T-cell assays have been described according to MIATA guidelines. Once the paper has been accepted following peer-review, authors will be requested to confirm their compliance (i.e. self- declaration) by email to [email protected] and include the complete reference and an image of the front page of your paper, if it is not open access. For more information on MIATA, see the MIATA website at http://miataproject.org/

MIFlowCyt

Flow cytometry experiments should be MIFlowCyt (Minimum Information about a flow cytometry experiment) compliant. Essential details of flow experiments should be displayed in order to allow others to accurately reproduce the experiments.

See also http://flowcyt.sourceforge.net/  or https://fairsharing.org/collection/MIBBI for further information.

Microarray data

Microarray experiments should be MIAME compliant, please see http://fged.org/projects/miame/ for more information. In addition, authors are encouraged to submit the complete microarray data relating to that published in the manuscript to an appropriate public database such as:

• GEO: www.ncbi.nlm.nih.gov/geo/
• Array Express: www.ebi.ac.uk/arrayexpress/ (scheduled to be replaced by https://www.ebi.ac.uk/biostudies/)
• GEA: https://www.ddbj.nig.ac.jp/gea/submit-array-e.html

Sequence Data

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:

• DNA Data Bank of Japan (DDBJ): www.ddbj.nig.ac.jp
• EMBL Nucleotide Archive: www.ebi.ac.uk/ena
• GenBank: www.ncbi.nlm.nih.gov/genbank

Protein sequence data should be submitted to either of the following repositories:

• Protein Information Resource (PIR): http://pir.georgetown.edu
• SWISS-PROT: www.expasy.ch/sprot/sprot-top.html

Structural Data

For papers describing structural data, atomic coordinates and the associated experimental data should be deposited in the appropriate databank (see below). Please note that the data in databanks must be released, at the latest, upon publication of the article. We trust in the cooperation of our authors to ensure that atomic coordinates and experimental data are released on time.

• Organic and organometallic compounds: Crystallographic data should not be sent as Supporting Information, but should be deposited with the Cambridge Crystallographic Data Centre (CCDC) at www.ccdc.cam.ac.uk/services/structure_deposit.
• Inorganic compounds: Fachinformationszentrum Karlsruhe (FIZ; https://icsd.products.fiz-karlsruhe.de/en/crystalstructure/crystal-structure-depot).
• Proteins and nucleic acids: Protein Data Bank (www.rcsb.org/pdb).
• NMR spectroscopy data: BioMagResBank (www.bmrb.wisc.edu).

Cover Image Submissions

This journal accepts artwork submissions for Cover Images. This is an optional service you can use to help increase article exposure and showcase your research. For more information, including artwork guidelines, pricing, and submission details, please visit the Journal Cover Image page.

Wiley Editing Services offers a professional cover image design service that creates eye-catching images, ready to be showcased on the journal cover.

Additional Guidelines for Cover Pictures and Table of Contents Graphics

• Concepts illustrated in graphical material must clearly fit with the research discussed in the accompanying text.
• Images featuring depictions or representations of people must not contain any form of objectification, sexualization, stereotyping, or discrimination. We also ask authors to consider community diversity in images containing multiple depictions or representations of people.
• Inappropriate use, representation, or depiction of religious figures or imagery, and iconography should be avoided.
• Use of elements of mythology, legends, and folklore might be acceptable and will be decided on a case-by-case basis. However, these images must comply with the guidelines on human participants when they are present.
• Generally, authors should consider any sensitivities when using images of objects that might have cultural significance or may be inappropriate in the context (for example, religious texts, historical events, and depictions of people).
• Legal requirements:
• All necessary copyright permission for the reproduction of the graphical elements used in visuals must be obtained prior to publication.
• Clearance must be obtained from identifiable people before using their image on the cover or the like and such clearance must specify that it will be used on the cover. Use within text does not require such clearance unless it discloses sensitive personal information such as medical information. In all situations involving disclosure of such personal info, specific permission must be obtained. And images of individuals should not be used in a false manner.

Graphics that do not adhere to these guidelines will be recommended for revision or will not be accepted for publication.

Transfer policies

Manuscripts that are not recommended for publication in the European Journal of Immunology due to a low priority rating, but that are well written and contain solid research, may be potential candidates for publication in Immunity, Inflammation and Disease, a peer-reviewed, open access, interdisciplinary journal providing rapid publication of high-quality research in immunology.

Sharing of materials

All materials and reagents that are not commercially available (antibodies, cell lines, constructs etc.) and associated protocols detailed in manuscripts published in the European Journal of Immunology are to be freely available to academic researchers in a timely manner upon request. The authors agree to this condition by submitting a manuscript to the European Journal of Immunology.